RT-310 is under clinical development by Resurge Therapeutics and currently in Phase I for Urinary Tract Infections. According to GlobalData, Phase I drugs for Urinary Tract Infections have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RT-310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RT-310 overview

RT-310 is under development for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. It is administered as an implant.

Resurge Therapeutics overview

Resurge Therapeutics specializes in the development of drug delivery solutions to treat local diseases, aiming to reduce the side effects and compliance requirements associated with oral and systemic medications. The company’s lead product in its pipeline is a novel drug delivery product designed for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia, a condition characterized by an enlarged prostate. It is headquartered in San Jose, California, the US.

For a complete picture of RT-310’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.